17,261 trials
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 42.9…
Melanoma
Primary: Determine the Overall Objective Response Rate (CR and PR). — 0; 6; 16; 27 participants
Sickle Cell Disease
Primary: SS RBC Adhesion (Epi -1d/cm2- vs. Sham) by Treatment — 0; -0.3; 7.4; 2.7 Percentage of total RBC
Major Upper or Lower Abdominal Surgery
Primary: SPID-12 — 22.41; 27.56; 2.93 units on a scale — p=<0.001
Neoplasms
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 52.9; 53.1 percentage of participants
Lymphoma · Multiple Myeloma · Leukemia
Primary: To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow…
Substance Abuse · Substance Dependence · Cognitive Impairment
Primary: Days of Sobriety in First 90 Days — 87.3; 84.64 Days of Sobriety — p=.55
Ischemia
Primary: Cohort 1: Determination of Rest Dose: Dose Acquistion Time Product — 100 MBq X Minutes
Pediculosis
Primary: Number of Participants Who Are Lice Free at All Follow-up Visits (Day 1, 7 and 14) Through the Day 14 Visit — 31; 42; 11 participants — p=<0.001
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Complete Response Rate — 35.3 percentage of participants
Prostate Cancer
Primary: Proportion of Patients Showing PSA Nadir — 83 percentage of patients with PSA nadir
Head and Neck Cancer
Primary: Compliance With Treatment . — 74 percentage of participants
Complicated Intra-abdominal Infection
Primary: Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis Population — 83.6…
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Subarachnoid Hemorrhage
Primary: Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk — .34; .30 mL/100 g/min